An observational study in Atopic Dermatitis Eczema and Prurigo Nodularis, sponsored by Peking University First Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2024-08-15.
Sponsored by Peking University First Hospital · Observational
In order to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for type 2 inflammatory skin diseases to systematically and effectively understand the current treatment status of patients with type 2 inflammatory skin diseases, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases and help patients with type 2 inflammatory skin diseases.
1,591 studies on the registry are indexed under Dermatitis, Atopic; 286 are open to participants now.
This study's planned enrollment of 100,000 is above the median of 150 across 282 observational studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →Peking University First Hospital is the lead sponsor of 390 studies on the registry; 186 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with Type 2 skin disease. Estimated number of patients: 100,000 (No age limit)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Demographics
Age, sex, ethnicity, body weight and height
Time frame: baseline
Age at Type 2 skin disease onset
Age of study patients at time of Type 2 skin disease onset
Time frame: baseline
Type of current Type 2 skin disease therapy
Type of therapy administered to treat Type 2 skin disease (e.g., systemic, topical, other)
Time frame: Baseline
Presence of Type 2 skin disease and selected comorbid conditions
Percentage of patients with Type 2 skin disease and selected comorbidities (e.g., asthma and allergic rhinitis) at baseline and during study
Time frame: Baseline to Month 120
Percentage of patients using specific Type 2 skin disease therapies and initiating new therapies
Percentage of patients using specific Type 2 skin disease therapies and initiating new therapies
Time frame: Baseline to Month 120
Eczema Area and Severity Index (EASI)
EASI score as assessed by physician
Time frame: Baseline to Month 120
Body Surface Area (BSA) percentage affected by Type 2 skin disease
BSA score as assessed by physician
Time frame: Baseline to Month 120
Patient Oriented Eczema Measure (POEM) questionnaire
POEM score as reported by the participant's caregiver
Time frame: Baseline to Month 120
Dermatology Life Quality Index
DLQI score as reported by the patients or caregivers
Time frame: Baseline to Month 120
Bullous Pemphigoid Disease Area Index(BPDAI)
BPDAI score as assessed by physician
Time frame: Baseline to Month 120
Autoimmune Bullous Skin Disorder Intensity Score (ABSIS)
ABSIS score as assessed by physician
Time frame: Baseline to Month 120
Chronic Urticaria Quality of Life questionnaire (CU-Q2oL)
CU-Q2oL score as assessed by patients or caregivers
Time frame: Baseline to Month 120
Urticaria Activity Score 7a （UAS7a）
UAS7a score as assessed by physician
Time frame: Baseline to Month 120
Urticaria Control test (UCT)
UCT score as assessed by patients or caregivers
Time frame: Baseline to Month 120
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2021 (actual). Primary completion is estimated for Dec 2031, 124 months after the start.
Of 96 non-industry observational studies under Dermatitis, Atopic, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 19. This study's planned 124 months is above that.
Counting every sponsor, half of 170 studies reached it within 35 months; a quarter within 17.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University First Hospital →